Open AccessInfluence of life intervention on anxiety, depression, and quality of life of COVID-19 patients
Author(s) -
Ye Qian,
Huan Xu,
Jing Diao,
Qiaozhen Li,
Qian Zhan,
Yujiao Fang
Publication year - 2021
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000025391
Subject(s) - medicine , anxiety , psychological intervention , quality of life (healthcare) , medline , meta analysis , randomized controlled trial , depression (economics) , psychiatry , intervention (counseling) , nursing , political science , law , economics , macroeconomics
Background: Coronavirus disease 2019 (COVID-19) patients suffer from anxiety, depression, and sleep disorder due to isolation treatment and other reasons. Whether life interventions can be an alternative therapy for COVID-19 patients, accompanied with anxiety, depression, and sleep disorder, is controversial. Therefore, we conducted a meta-analysis and systematic review to evaluate the effects of life interventions on anxiety, depression, and sleep disorder in COVID-19 patients to provide some guidance for clinical application. Methods: The randomized controlled trials related to the life intervention and COVID-19 from inception to February 2021 will be searched. The following databases are our focused areas: the Cochrane Central Register of Controlled Trials, PubMed, MEDLINE, EMBASE, Web of Science, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, and Wan Fang Database. Two investigators would independently screen the literature according to the inclusion and exclusion criteria, extract data, and evaluate the risk of bias in the included studies. Meta-analysis was performed with RevMan 5.3 software. Results: The results will provide a high-quality synthesis of current evidence for researchers in this subject area. Conclusion: The conclusion of our study will provide evidence for the judgment of whether life intervention is an effective intervention on COVID-19 patients. PROSPERO registration number: CRD42020199802.